(Q30747958)

26 June 2017

1 reference

title

Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma (English)

1 reference

26 June 2017

author name string

Marie-France Demierre

series ordinal

1 reference

26 June 2017

Youn H Kim

series ordinal

1 reference

26 June 2017

Herschel S Zackheim

series ordinal

1 reference

26 June 2017

publication date

1 December 2003

1 reference

Hematology / Oncology Clinics of North America

26 June 2017

published in

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

page(s)

1485-1507

1 reference

Rationale of a new classification for the group of primary cutaneous lymphomas

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognostic variables in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Clinical staging for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognostic clinicopathologic factors in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognostic factor analysis in mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognostic Factors in Erythrodermic Mycosis Fungoides and the Sézary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

The changing survival of patients with mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Detection of a Peripheral Blood T Cell Clone is an Independent Prognostic Marker in Mycosis Fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Role of histology in providing prognostic information in mycosis fungoides.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Molecular genetics of cutaneous lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Extracorporeal photopheresis and interferon-α in advanced cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Assessing clinical outcomes in cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Photopheresis therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Combined modality therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Topical corticosteroids for mycosis fungoides. Experience in 79 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

"High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Why does a higher response rate to chemotherapy correlate poorly with improved survival?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Guidelines for reporting outcomes of lymphoma trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Sample size slippages in randomised trials: exclusions and the lost and wayward

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Advances in quality of life measurements in oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Assessment of quality-of-life outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Measuring health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Quality of life and the patient with cancer. Individual and policy implications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Understanding research about quality of life and other health outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients With Skin Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Quantifying the harmful effect of psoriasis on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Science, language, intuition, and the many meanings of quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Lessons learned from measuring health-related quality of life in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Treating the patient, not just the cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Spirituality and the dying patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

Scalpdex: a quality-of-life instrument for scalp dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900111-4

7 January 2021

10.1016/S0889-8588(03)00111-4

Identifiers

DOI

1 reference

26 June 2017

1 reference